tetano
Editor, Senior Moderator
CEN Case Rep
. 2022 Mar 9.
doi: 10.1007/s13730-022-00697-z. Online ahead of print.
A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection
Hiroko Beppu[SUP] 1 [/SUP], Toshie Ogawa[SUP] 2 [/SUP], Masahiro Ishikane[SUP] 3 [/SUP], Tomoko Kawanishi[SUP] 2 [/SUP], Tatsuya Fukuda[SUP] 4 5 [/SUP], Lubuna Sato[SUP] 3 [/SUP], Akihiro Matsunaga[SUP] 6 [/SUP], Kenji Maeda[SUP] 7 [/SUP], Daisuke Katagiri[SUP] 8 [/SUP], Yukihito Ishizaka[SUP] 6 [/SUP], Hiroaki Mitsuya[SUP] 7 [/SUP], Norio Ohmagari[SUP] 3 [/SUP], Fumihiko Yasui[SUP] 9 [/SUP], Michinori Kohara[SUP] 9 [/SUP], Kan Kikuchi[SUP] 10 [/SUP], Sachiko Wakai[SUP] 2 [/SUP]
Affiliations
Abstract
Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.
Keywords: COVID-19; End-stage renal disease; Hemodialysis; Reinfection; Severe acute respiratory syndrome coronavirus 2 antibodies.
. 2022 Mar 9.
doi: 10.1007/s13730-022-00697-z. Online ahead of print.
A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection
Hiroko Beppu[SUP] 1 [/SUP], Toshie Ogawa[SUP] 2 [/SUP], Masahiro Ishikane[SUP] 3 [/SUP], Tomoko Kawanishi[SUP] 2 [/SUP], Tatsuya Fukuda[SUP] 4 5 [/SUP], Lubuna Sato[SUP] 3 [/SUP], Akihiro Matsunaga[SUP] 6 [/SUP], Kenji Maeda[SUP] 7 [/SUP], Daisuke Katagiri[SUP] 8 [/SUP], Yukihito Ishizaka[SUP] 6 [/SUP], Hiroaki Mitsuya[SUP] 7 [/SUP], Norio Ohmagari[SUP] 3 [/SUP], Fumihiko Yasui[SUP] 9 [/SUP], Michinori Kohara[SUP] 9 [/SUP], Kan Kikuchi[SUP] 10 [/SUP], Sachiko Wakai[SUP] 2 [/SUP]
Affiliations
- PMID: 35266095
- DOI: 10.1007/s13730-022-00697-z
Abstract
Hemodialysis patients are vulnerable to severe and lethal COVID-19, and their protective immunity against COVID-19 is not yet fully understood. Therefore, we report a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and discuss the role of antibodies in SARS-CoV-2 infection. A hemodialysis patient developed asymptomatic COVID-19 due to an outbreak in a hospital on October 29th, 2020. As he was hospitalized and did not develop any symptoms, he was discharged on November 9th. On January 18th, he presented with symptomatic COVID-19 due to close household contact. Then, he developed respiratory failure and was transferred to National Center for Global Health and Medicine if he would need intensive care. He recovered with oxygen inhalation, favipiravir, and steroid treatment, and was discharged on February 12th. To evaluate anti-SARS-CoV-2 antibodies during two hospital stays, we measured immunoglobulin (Ig) G specific for S1 subunit of Spike (S) protein of SARS-CoV-2 (IgG-S1) , IgG specific for the full-length S protein (anti-Spike IgG) and neutralizing antibodies. No seroconversion occurred 5 days after initial infection, the seroconversion of IgG-S1 was observed 10 days after the second infection. Similar to IgG-S1 antibody titer results, anti-Spike IgG and neutralizing antibodies increased from 12 days after the second infection. In conclusion, we experienced a case of COVID-19 reinfection in a hemodialysis patient 81 days after the first episode and showed the kinetics and role of antibodies in SARS-CoV-2 infection. Further studies are needed to understand SARS-CoV-2 reinfection risk in hemodialysis patients and its clinical significance.
Keywords: COVID-19; End-stage renal disease; Hemodialysis; Reinfection; Severe acute respiratory syndrome coronavirus 2 antibodies.